IL152315A - Soluble mutant ALTC4 molecules and pharmaceutical preparations containing them - Google Patents

Soluble mutant ALTC4 molecules and pharmaceutical preparations containing them

Info

Publication number
IL152315A
IL152315A IL152315A IL15231501A IL152315A IL 152315 A IL152315 A IL 152315A IL 152315 A IL152315 A IL 152315A IL 15231501 A IL15231501 A IL 15231501A IL 152315 A IL152315 A IL 152315A
Authority
IL
Israel
Prior art keywords
ctla4 mutant
mutant molecule
molecule
ctla4
cell
Prior art date
Application number
IL152315A
Other languages
English (en)
Hebrew (he)
Other versions
IL152315A0 (en
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL152315A0 publication Critical patent/IL152315A0/xx
Publication of IL152315A publication Critical patent/IL152315A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL152315A 2000-05-26 2001-05-23 Soluble mutant ALTC4 molecules and pharmaceutical preparations containing them IL152315A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Publications (2)

Publication Number Publication Date
IL152315A0 IL152315A0 (en) 2003-05-29
IL152315A true IL152315A (en) 2010-04-15

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
IL152315A IL152315A (en) 2000-05-26 2001-05-23 Soluble mutant ALTC4 molecules and pharmaceutical preparations containing them

Country Status (41)

Country Link
EP (3) EP3029062A1 (en:Method)
JP (1) JP4328525B2 (en:Method)
KR (2) KR100895134B1 (en:Method)
CN (2) CN101255192A (en:Method)
AR (1) AR031699A1 (en:Method)
AT (1) ATE271066T1 (en:Method)
AU (2) AU6346601A (en:Method)
BE (1) BE2011C041I2 (en:Method)
BR (1) BRPI0111191B8 (en:Method)
CA (1) CA2409748C (en:Method)
CY (2) CY2011019I2 (en:Method)
CZ (1) CZ304451B6 (en:Method)
DE (2) DE60104282T2 (en:Method)
DK (1) DK1248802T3 (en:Method)
EC (1) ECSP024365A (en:Method)
EE (2) EE05557B1 (en:Method)
EG (1) EG24459A (en:Method)
ES (2) ES2571852T3 (en:Method)
FR (1) FR11C0053I2 (en:Method)
GE (1) GEP20053658B (en:Method)
HK (1) HK1048126B (en:Method)
HU (2) HU228137B1 (en:Method)
IL (1) IL152315A (en:Method)
LT (1) LT5133B (en:Method)
LU (1) LU91902I2 (en:Method)
LV (1) LV12994B (en:Method)
MX (1) MXPA02011534A (en:Method)
MY (1) MY136113A (en:Method)
NO (2) NO330797B1 (en:Method)
PE (1) PE20011338A1 (en:Method)
PL (1) PL206267B1 (en:Method)
PT (1) PT1248802E (en:Method)
RU (1) RU2283847C2 (en:Method)
SI (1) SI1248802T1 (en:Method)
SK (1) SK288131B6 (en:Method)
TR (1) TR200402703T4 (en:Method)
TW (2) TWI314933B (en:Method)
UA (1) UA87432C2 (en:Method)
UY (1) UY26723A1 (en:Method)
WO (1) WO2001092337A2 (en:Method)
ZA (1) ZA200208944B (en:Method)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
HU226847B1 (en) * 2000-07-03 2009-12-28 Bristol Myers Squibb Co Use of soluble ctla4 molecules for treating of rheumatoid arthritis
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
ATE390931T1 (de) 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
WO2003088991A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
CN101857851A (zh) * 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
SI1576182T2 (sl) * 2002-12-23 2020-07-31 Bristol-Myers Squibb Company Izboljšava kvalitete izdelka v procesih pridelave beljakovin v celični kulturi sesalcev
PL378879A1 (pl) 2002-12-30 2006-05-29 Amgen Inc. Terapia skojarzona z czynnikami kostymulującymi
EP1684791A4 (en) 2003-10-27 2009-07-01 Amgen Inc COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
US10508144B2 (en) 2005-12-20 2019-12-17 Bristol-Myers Squibb Company Carbohydrate content of CTLA4 molecules
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
EP2716657A3 (en) 2006-12-20 2014-10-08 Mmrglobal, Inc. Antibodies and methods for making and using them
CN101998965B (zh) 2007-11-01 2014-03-12 安斯泰来制药有限公司 免疫抑制性多肽与核酸
PT2344540T (pt) 2008-10-02 2018-02-02 Aptevo Res & Development Llc Proteínas de ligação multi-alvo antagonistas de cd86
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2011113019A2 (en) * 2010-03-12 2011-09-15 Abbott Biotherapeutics Corp. Ctla4 proteins and their uses
AU2012220861A1 (en) 2011-02-23 2013-09-05 Amgen Inc. Cell culture media for UVC exposure and methods related thereto
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
CA2868748C (en) * 2012-05-11 2022-07-26 Medimmune, Llc Ctla-4 variants
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
EP2866823A4 (en) 2012-06-27 2016-03-02 Orban Biotech Llc CTLA4 FUSION PROTEINS FOR THE TREATMENT OF DIABETES
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
EP3094735A1 (en) 2014-01-13 2016-11-23 Amgen Inc. Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
PL3152317T3 (pl) 2014-06-04 2019-08-30 Amgen Inc. Sposoby zbierania hodowli ssaczych komórek
MX385409B (es) 2014-12-01 2025-03-04 Amgen Inc Proceso para manipular el nivel de contenido de glicano de una glicoproteína.
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
ES2870991T3 (es) 2015-04-17 2021-10-28 Alpine Immune Sciences Inc Proteínas inmunomoduladoras con afinidades ajustables
AU2016321298A1 (en) 2015-09-09 2018-03-29 The Trustees Of Columbia University In The City Of New York Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
EP3374493A1 (en) 2015-11-09 2018-09-19 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
CN116942793A (zh) * 2016-09-19 2023-10-27 昂科医药 Cd80和cd86结合蛋白组合物及其用途
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
MX2019012567A (es) 2017-04-20 2020-02-13 Egenesis Inc Metodos para generar animales geneticamente modificados.
US11753458B2 (en) 2017-10-10 2023-09-12 Alpine Immune Sciences, Inc. CTLA-4 variant immunomodulatory proteins and uses thereof
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
US20220281939A1 (en) 2019-08-27 2022-09-08 Tonix Pharma Limited Modified tff2 polypeptides
NZ781145A (en) 2019-12-06 2023-05-26 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
KR20230026434A (ko) 2020-06-18 2023-02-24 리제너론 파아마슈티컬스, 인크. 미처리된 c-말단 리신을 정확하게 측정하기 위한 중질 펩티드 접근법
CN116601279A (zh) 2020-07-28 2023-08-15 思进股份有限公司 用于生产多肽的方法和系统
WO2023115027A2 (en) 2021-12-16 2023-06-22 Bristol-Myers Squibb Company Detergent for viral inactivation
WO2023167855A1 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
WO1993000431A1 (en) * 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
WO2000019988A1 (en) * 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
HU226847B1 (en) * 2000-07-03 2009-12-28 Bristol Myers Squibb Co Use of soluble ctla4 molecules for treating of rheumatoid arthritis

Also Published As

Publication number Publication date
UA87432C2 (uk) 2009-07-27
BRPI0111191B1 (pt) 2019-12-31
NO2011027I2 (en:Method) 2011-12-15
AU2001263466C1 (en) 2006-10-26
BRPI0111191B8 (pt) 2021-05-25
JP4328525B2 (ja) 2009-09-09
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
DK1248802T3 (da) 2004-11-15
ECSP024365A (es) 2003-03-31
SI1248802T1 (en) 2005-02-28
HU228137B1 (en) 2012-12-28
DE122011100063I1 (de) 2012-06-14
HK1048126A1 (en) 2003-03-21
ES2225549T3 (es) 2005-03-16
EP1248802B1 (en) 2004-07-14
FR11C0053I1 (en:Method) 2012-01-13
ES2571852T3 (es) 2016-05-27
EE05557B1 (et) 2012-08-15
PE20011338A1 (es) 2002-01-13
CN101255192A (zh) 2008-09-03
FR11C0053I2 (fr) 2013-01-11
NO20025656L (no) 2002-11-25
HUS1300012I1 (hu) 2016-08-29
KR100895134B1 (ko) 2009-05-04
CA2409748C (en) 2008-09-16
DE60104282T2 (de) 2005-10-13
KR20030009502A (ko) 2003-01-29
PL206267B1 (pl) 2010-07-30
TWI314933B (en) 2009-09-21
NO330797B1 (no) 2011-07-18
EP1536234A3 (en) 2009-06-03
LV12994B (en) 2003-08-20
CZ20023892A3 (cs) 2003-09-17
ATE271066T1 (de) 2004-07-15
GEP20053658B (en) 2005-11-10
TW200906857A (en) 2009-02-16
EP1536234B1 (en) 2016-03-16
CN1309735C (zh) 2007-04-11
MXPA02011534A (es) 2004-08-12
EE201100050A (et) 2011-10-17
NO20025656D0 (no) 2002-11-25
PL366231A1 (en) 2005-01-24
EP1536234A2 (en) 2005-06-01
CY2011019I1 (el) 2016-12-14
EP1248802B9 (en) 2005-05-11
DE60104282D1 (de) 2004-08-19
MY136113A (en) 2008-08-29
LT2002114A (en) 2003-12-29
HUP0302201A2 (hu) 2003-10-28
EP3029062A1 (en) 2016-06-08
CZ304451B6 (cs) 2014-05-14
JP2004511213A (ja) 2004-04-15
TR200402703T4 (tr) 2004-11-22
UY26723A1 (es) 2001-12-28
PT1248802E (pt) 2004-11-30
SK288131B6 (sk) 2013-10-02
HK1071931A1 (en) 2005-08-05
CY1117625T1 (el) 2017-04-26
HK1048126B (en) 2005-03-04
IL152315A0 (en) 2003-05-29
EE05458B1 (et) 2011-08-15
AU2001263466B2 (en) 2006-04-27
HUP0302201A3 (en) 2010-01-28
WO2001092337A3 (en) 2002-05-10
BE2011C041I2 (en:Method) 2020-08-20
AU6346601A (en) 2001-12-11
KR100889887B1 (ko) 2009-03-24
WO2001092337A2 (en) 2001-12-06
RU2283847C2 (ru) 2006-09-20
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
CN1441810A (zh) 2003-09-10
SK15702002A3 (sk) 2004-01-08
EG24459A (en) 2009-07-16
NO2011027I1 (no) 2012-01-09
BR0111191A (pt) 2004-07-06
AR031699A1 (es) 2003-10-01
EE200200659A (et) 2004-06-15
CA2409748A1 (en) 2001-12-06
TWI319405B (en) 2010-01-11
ZA200208944B (en) 2004-02-13
LT5133B (lt) 2004-05-25

Similar Documents

Publication Publication Date Title
IL152315A (en) Soluble mutant ALTC4 molecules and pharmaceutical preparations containing them
RU2002131588A (ru) Растворимый мутантный ctla4 и его применение
JP7637415B2 (ja) インターロイキン－２バリアントおよびその使用方法
AU2013301562B2 (en) Interleukin-2 fusion proteins and uses thereof
JP4787750B2 (ja) Ｃｄ２０結合性ポリペプチド構成物
AU640115B2 (en) Cloning and expression of transforming growth factor beta-2
CN110520445B (zh) 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备
RU2004115039A (ru) Растворимые мутантные молекулы ctla4
RU2006127554A (ru) Fc-эритропоэтин слитый белок с улучшенной фармакокинетикой
CN114728040A (zh) 新型白介素-2变体及其双功能融合分子
CN114051500A (zh) 包含白细胞介素-2突变体和抗cd8抗体的免疫缀合物
CN110563850A (zh) 靶向/免疫调节性融合蛋白及其制造方法
KR102247704B1 (ko) 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법
WO2019155408A1 (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing same
CA2430135A1 (en) Recombinant anti-cd30 antibodies and uses thereof
JP2023521238A (ja) 免疫複合体
NZ244281A (en) Hybrid recombinant protein coded for by a two part fused sequence comprising a human il-5 dna sequence and an immunoglobulin dna sequence; processes
CA2560278A1 (en) Modified bouganin proteins, cytotoxins and methods and uses thereof
IL130123A (en) LAG-3 protein mutants, their expression, use and method of production
CN111808192A (zh) 结合lag3的抗体及其用途
CN113939534A (zh) 具有降低的断裂的抗αβTCR结合多肽
US20200377588A1 (en) Highly Versatile Method of Presenting Cyclic Peptide on Protein Structure
US20230340054A1 (en) Interleukin-2 muteins and uses thereof
WO1995014779A1 (en) Mutated hig-e fragments and derivative thereof
JP2003529370A5 (en:Method)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
EXTF Application for patent extension filed
KB Patent renewed
PEL Intention of commissioner to extend period of protection

Free format text: PRODUCT NAME: BELATACEPT

Extension date: 20250615

KB Patent renewed